Cover Image
Market Research Report

Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth

Published by GBI Research Product code 246719
Published Content info 141 Pages
Immediate Delivery Available
Price
Back to Top
Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth
Published: July 10, 2012 Content info: 141 Pages
Description

Summary

GBI Research, the leading business intelligence provider, has released its latest report, "Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth" that provides key data, information and analysis of the major trends and issues affecting the biosimilar market in developed countries covering the US, the top five European markets and Japan. The report provides a comprehensive insight into the biosimilar market, and offers market forecasts by geography as well as biosimilar categories. It also provides the drivers and restraints affecting the biosimilars market, as well as the business environment and the key success factors in the global biosimilar industry. In addition, the report describes the regulatory environment in the US, top five European markets and Japan with respect to biosimilars. Finally, the report looks into the competitive landscape of the biosimilar industry by offering profiles of key players in the industry and the analysis of major deals that have taken place.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The global biosimilars industry has grown significantly over the past few years and has a great scope for future growth due to the expiry of patents for major biological drugs, pressure on the governments of developed nations to cut healthcare costs and the savings in treatment costs offered by biosimilars. The global biosimilar industry was valued at $450m in 2011 and is expected to increase to $7.5billion in 2018 at a compound annual growth rate (CAGR) of 49.6%. Access to the US market after the issuance of draft guidelines by the US Food and Drug Administration (FDA) will offer a major boost to the growth of the global biosimilar market. The establishment of guidelines for the approval of biosimilar interferons in the European Union will also drive global biosimilar market growth.

Currently, the global biosimilar market is at nascent stage. Major pharmaceutical companies including Teva Pharmaceuticals, Sandoz and Hospira have made a strong position for themselves in the European biosimilar market. However, the markets in the US and Japan have not been explored fully. Companies such as Pfizer, Mylan and Merck have shown interest in the opportunities offered by the global biosimilar market and have taken initiatives enter into it. Players such as Biocon and Celltrion from the emerging economies are collaborating with these global pharmaceutical companies to develop and market biosimilars. The market is expected to witness a large amount of strategic consolidation between these players in near future.

Scope

  • Data and analysis on the biosimilar market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Market forecast for global biosimilar market from 2011 to 2018, by geography as well as product category.
  • Key drivers and restraints that have had a significant impact on the market globally as well as at national level.
  • The regulatory environment for biosimilars in the US, the EU and in Japan.
  • Analysis of competitive environment in the industry and profiles of key players in the biosimilar market. The companies studied in this report are Sandoz, Teva Pharmaceuticals, Hospira, Dr. Reddy's, Biocon, Intas, Celltrion and 3S Bio.
  • Key M&A activities and Licensing Agreements that took place between 2009 up until February 2012 in the global biosimilar market.

Reasons to buy

  • Make more informed business decisions from the insightful and in-depth analysis of the global biosimilar market and the factors shaping it.
  • Identify the key areas of deal making through a thorough understanding of the deals landscape in the global biosimilar market.
  • Build effective strategies to launch pipeline products by identifying potential geographies.
  • Identify the companies from emerging nations for collaborations along with their key capabilities.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill your portfolio gaps.

Executive Summary

Only FDA Approval Pathway Complications are Holding Back the US Biosimilars Flood.

New guidelines laid out by the US Food and Drug Administration (FDA) lack clarity and specificity, meaning that a wealth of biosimilars are currently restricted from the world's biggest pharmaceutical market, states a new report from healthcare industry analysts GBI Research.

The report* says that ambiguity within the healthcare authority's approval pathway procedure suggests decisions will be made on a case-by-case basis, hindering the flow of biosimilars into the US market.

As biosimilars require high investments and long periods of development compared to generics, companies need to know in advance what US regulators will require when they submit their applications for the approval of a new product.

GBI Research expects the first biosimilar to be approved in the US by the end of this year, followed by products by Sandoz and Hospira in early 2013. Once these medications have broken through, and a clearer approval pathway is established, an abundance of biosimilars is expected to follow and take advantage of the highly lucrative US pharmaceutical market.

Europe has already approved 14 biosimilars - the highest of any region - with a range of products belonging to the erythropoietin (EPO) and granulocyte colony stimulating factors (G-CSF) and human growth hormones (HGH) groups. Japan launched its first biosimilar in October 2009.

The reduction of healthcare expenditure is at the top of the agenda for national healthcare authorities around the globe, and as biologics are among the highest priced therapies in the world, establishing governing regulations is a key focus.

GBI Research predicts that the value of the worldwide biologics market will rocket from $450m in 2011 to $7.5 billion in 2018, climbing at a highly impressive Compound Annual Growth Rate (CAGR) of 49.6%. This staggering jump is attributed to the entrance of the US into the global biologics market.

Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth

This report provides key data, information and analysis of the major trends and issues affecting the biosimilar market in developed countries covering the US, the top five European markets and Japan

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

3. Biosimilars in Developed Countries- Market Overview

  • 3.1. Introduction
  • 3.2. Biologics and Small Molecules
    • 3.2.1. Structural Differences between Biologics and Small Molecules
  • 3.3. Market Size and Patent Expiries of Branded Biologics
    • 3.3.1. Market Size of Branded Biologics & Sales by Major Drug Classes in 2010
    • 3.3.2. Top Ten Biologics in 2010
    • 3.3.3. Patent Expiry of Leading Biologics, 2011-2018
  • 3.4. Approved Biosimilars in Europe until December 2011
  • 3.5. Biopharmaceutical and Biosimilars Manufacturing and Development Process
    • 3.5.1. Manufacturing Process
    • 3.5.2. Setting up a new biosimilar manufacturing facility
    • 3.5.3. Development Process & Cost

4. Biosimilars in Developed Countries- Geographic Landscape

  • 4.1. Introduction
  • 4.2. Global Biosimilar Market
    • 4.2.1. Market Size and Forecast
    • 4.2.2. Drivers and Barriers
  • 4.3. US Biosimilar Market
    • 4.3.1. Market Size and Forecast
    • 4.3.2. Regulatory Landscape
    • 4.3.3. Objectives of Biosimilar Legislation and Regulatory Frameworks
    • 4.3.4. Regulatory Framework for Biopharmaceutical Industry
    • 4.3.5. Evolution of Regulatory Pathways for Biosimilars
    • 4.3.6. BPCI Act and the Pathway for Approval of Biosimilar Products
    • 4.3.7. Drivers and Barriers
  • 4.4. Top Five European Markets- Biosimilar Market Size and Forecast
    • 4.4.1. Introduction
    • 4.4.2. Market Size and Forecast
    • 4.4.3. Regulatory Framework for Biopharmaceutical Industry
    • 4.4.4. Evolution of Regulatory Pathways for Biosimilars
    • 4.4.5. Current Position on Biosimilars
    • 4.4.6. The Bolar Type Provision
    • 4.4.7. The Comparability Exercise
    • 4.4.8. Biosimilars Approvals and Applications
    • 4.4.9. EMA Guidelines for Biosimilar mAb
    • 4.4.10. European Biosimilars Industry- Issues
    • 4.4.11. Drivers and Barriers
    • 4.4.12. Country Analysis - The UK
    • 4.4.13. Country Analysis - Germany
    • 4.4.14. Country Analysis - France
    • 4.4.15. Country Analysis - Spain
    • 4.4.16. Country Analysis - Italy
  • 4.5. Japan Biosimilars Market Size and Forecasts
    • 4.5.1. Market Size and Forecast
  • 4.6. Regulatory Landscape in Japan
    • 4.6.1. Regulatory Framework for Biopharmaceutical Industry
    • 4.6.2. Evolution of Regulatory Pathways for Biosimilars
    • 4.6.3. Current Position on Biosimilars
    • 4.6.4. Drivers and Barriers

5. Biosimilars in Developed Countries - Market Characterization

  • 5.1. Human Growth Hormone Biosimilars Market
    • 5.1.1. Pipeline molecules
    • 5.1.2. Drivers and barriers
  • 5.2. Erythropoietin (EPO) Biosimilars Market
    • 5.2.1. Pipeline molecules
    • 5.2.2. Drivers and barriers
  • 5.3. Granulocyte-Colony Stimulating Factor (G-CSF) Biosimilars Market
    • 5.3.1. Pipeline molecules
    • 5.3.2. Drivers and barriers
  • 5.4. Interferon alpha Biosimilars Market
    • 5.4.1. Pipeline molecules
  • 5.5. Interferon beta Biosimilars Market
    • 5.5.1. Pipeline molecules
    • 5.5.2. Interferon alpha and Interferon beta Drivers and Barriers
  • 5.6. Insulin and Insulin Analogs Biosimilars Market
    • 5.6.1. Pipeline molecules
    • 5.6.2. Drivers and barriers
  • 5.7. TNF-alpha Inhibitor Biosimilars Market
    • 5.7.1. Pipeline molecules
    • 5.7.2. Drivers and barriers
  • 5.8. Biosimilars Market for Monoclonal Antibodies against Cancer
    • 5.8.1. Pipeline molecules
    • 5.8.2. Drivers and barriers

6. Biosimilars in Developed Countries- Case Study

  • 6.1. Market Share of Biosimilars in Top Five European Markets
    • 6.1.1. Market Share - Filgrastim
    • 6.1.2. Market Share- Somatropin
    • 6.1.3. Market Share- EPO
  • 6.2. Pricing of Biosimilars in Top Five European Markets
  • 6.3. Strategies Adopted By Branded Biologic Companies to Beat Generic Competition
    • 6.3.1. Introduction
    • 6.3.2. Second Generation Biologics
    • 6.3.3. New Formulation
    • 6.3.4. Combination Products
    • 6.3.5. New Approved Indications
    • 6.3.6. Caps
  • 6.4. Industry Dynamics- Strategies to Be Adopted by Companies to Enter the Biosimilar Market
    • 6.4.1. Product
    • 6.4.2. Price
    • 6.4.3. Place
    • 6.4.4. Promotion
    • 6.4.5. People

7. Biosimilars in Developed Countries-Competitive Landscape

  • 7.1. Celltrion
    • 7.1.1. Company Profile
    • 7.1.2. SWOT Analysis
  • 7.2. Dr Reddy's Laboratories
    • 7.2.1. Company Profile
    • 7.2.2. SWOT Analysis
  • 7.3. Hospira
    • 7.3.1. Company Profile
    • 7.3.2. SWOT Analysis
  • 7.4. Biocon
    • 7.4.1. Company Profile
    • 7.4.2. SWOT Analysis
  • 7.5. Teva Pharmaceuticals Ltd
    • 7.5.1. Company Profile
    • 7.5.2. SWOT Analysis
  • 7.6. Sandoz
    • 7.6.1. Company Profile
    • 7.6.2. SWOT Analysis
  • 7.7. 3SBio
    • 7.7.1. Company Profile
    • 7.7.2. SWOT Analysis
  • 7.8. Intas Pharma
    • 7.8.1. Company Profile
    • 7.8.2. SWOT Analysis
  • 7.9. Samsung Biologics
    • 7.9.1. Company Profile
    • 7.9.2. SWOT Analysis

8. Biosimilars in Developed Countries- Strategic Consolidations

  • 8.1. Deals by Type
  • 8.2. Mergers & Acquisitions (M&A)
    • 8.2.1. M&A Deals by Year
    • 8.2.2. M&A Deals by Value
    • 8.2.3. M&A Deals by Geography
    • 8.2.4. M&A Deals in 2011
  • 8.3. Licensing Agreements in the Biosimilars Market
    • 8.3.1. Licensing Agreements By Year
    • 8.3.2. Licensing Agreements By Value
    • 8.3.3. Licensing Agreements By Geography
    • 8.3.4. Licensing Agreement Deals
  • 8.4. Co- Development Deals
    • 8.4.1. Co-Development Deals By Year
    • 8.4.2. Co-Development Deals By Value
    • 8.4.3. Co-Development Deals By Geography
    • 8.4.4. Co-Development Deals

9. Biosimilars in Developed Countries- Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Bibliography
  • 9.4. Research Methodology
    • 9.4.1. Market Overview
    • 9.4.2. Geographic Landscape
    • 9.4.3. Market Characterization
    • 9.4.4. Case Study
    • 9.4.5. Competitive Landscape
    • 9.4.6. Strategic Consolidations
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: Biosimilars in Developed Countries, Patent Expiry of Leading Biologics 2011-2018
  • Table 2: Biosimilars in Developed Countries, European Union, Approved Biosimilars up to 2011
  • Table 3: Biosimilars in Developed Countries, Global, Market Forecasts ($m), 2011-2018
  • Table 4: Biosimilars in Developed Countries, US Biosimilars Market, Revenue Forecasts, ($m), 2011-2018
  • Table 5: Biosimilars in Developed Countries, European Biosimilars Market, Revenue Forecasts ($m), 2011-2018
  • Table 6: Biosimilars in Developed Countries, Biosimilar Approvals, Europe, 2011
  • Table 7: Biosimilars in Developed Countries, Japan Biosimilar Market, Revenue Forecasts ($m), 2011-2018
  • Table 8: Biosimilars in Developed Countries, Human Growth Hormone Biosimilars Market, Revenue Forecasts ($m), 2011-2018
  • Table 9: Biosimilars in Developed Countries, Human Growth Hormone Biosimilars Market, Pipeline Molecules, 2011
  • Table 10: Biosimilars in Developed Countries, Erythropoietin Biosimilars Market, Revenue Forecasts ($m), 2011-2018
  • Table 11: Biosimilars in Developed Countries, Erythropoietin Biosimilars Market, Pipeline Molecules Phase III , 2011
  • Table 12: Biosimilars in Developed Countries, Epoetin Alfa, Pipeline Molecules Phase I , 2011
  • Table 13: Biosimilars in Developed Countries, Erythropoietin Biosimilars Market, Pipeline Molecules Filed , 2011
  • Table 14: Biosimilars in Developed Countries, Erythropoietin Biosimilars Market, Pipeline Molecules Pre-Clinical , 2011
  • Table 15: Biosimilars in Developed Countries, Granulocyte-Colony Stimulating Factor Biosimilars Market, Revenue Forecasts ($m), 2011-2018
  • Table 16: Biosimilars in Developed Countries, Granulocyte-Colony Stimulating Factor Biosimilars Market, Pipeline Molecules Phase III , 2011
  • Table 17: Biosimilars in Developed Countries, Granulocyte-Colony Stimulating Factor Biosimilars Market, Pipeline Molecules Phase I , 2011
  • Table 18: Biosimilars in Developed Countries, Granulocyte-Colony Stimulating Factor Biosimilars Market, Pipeline Molecules Pre-clinical, 2011
  • Table 19: Biosimilars in Developed Countries, Granulocyte-Colony Stimulating Factor Biosimilars Market, Pipeline Molecules Filed, 2011
  • Table 20: Biosimilars in Developed Countries, Interferon alpha Biosimilars Market, Revenue Forecasts ($m), 2012-2018
  • Table 21: Biosimilars in Developed Countries, Interferon alpha Biosimilars Market, Pipeline Molecules, 2011
  • Table 22: Biosimilars in Developed Countries, Interferon beta Biosimilars Market, Revenue Forecasts ($m), 2012-2018
  • Table 23: Biosimilars in Developed Countries, Interferon beta Biosimilars Market, Pipeline Molecules, 2011
  • Table 24: Biosimilars in Developed Countries, Insulin and Insulin Analogs Biosimilars Market, Revenue Forecasts ($m), 2012-2018
  • Table 25: Biosimilars in Developed Countries, Insulin and Insulin Analogs Biosimilars Market, Pipeline Molecules, 2011
  • Table 26: Biosimilars in Developed Countries, TNF-alpha Inhibitor Biosimilars Market, Revenue Forecasts ($m), 2015-2018
  • Table 27: Biosimilars in Developed Countries, TNF-alpha Inhibitor Biosimilars Market, Pipeline Molecules, 2012
  • Table 28: Biosimilars in Developed Countries, Biosimilars Market for Monoclonal Antibodies Against Cancer, Revenue Forecasts ($m), 2014-2018
  • Table 29: Biosimilars in Developed Countries, Biosimilars Market for Monoclonal Antibodies Against Cancer, Pipeline Molecules, 2011
  • Table 30: Biosimilars in Developed Countries, Strategic Consolidations, Deals by Type, 2009-2012
  • Table 31: Biosimilars in Developed Countries, Strategic Consolidations, M&A Deals by Year, 2009-2011
  • Table 32: Biosimilars in Developed Countries, Strategic Consolidations, M&A Deals by Value*, 2009-2011
  • Table 33: Biosimilars in Developed Countries, Strategic Consolidations, M&A Deals by Geography, 2009-2011
  • Table 34: Biosimilars in Developed Countries, Strategic Consolidations, M&A Deals by Value, 2011
  • Table 35: Biosimilars in Developed Countries, Strategic Consolidations, Licensing Deals by Year, 2009-2011
  • Table 36: Biosimilars in Developed Countries, Strategic Consolidations, Licensing Deals by Value, 2009-2011
  • Table 37: Biosimilars in Developed Countries, Strategic Consolidations, Licensing Deals by Geography, 2009-2011
  • Table 38: Biosimilars in Developed Countries, Strategic Consolidations, Licensing Deals, 2011
  • Table 39: Biosimilars in Developed Countries, Strategic Consolidations, Co- Development Deals by Year, 2010-2011
  • Table 40: Biosimilars in Developed Countries, Strategic Consolidations, Co-Development Deals by Value, 2009-2012
  • Table 41: Biosimilars in Developed Countries, Strategic Consolidations, Co-Development Deals by Geography, 2009-2012
  • Table 42: Biosimilars in Developed Countries, Strategic Consolidations, Co-Development Deals, 2011-2012

List of Figures

  • Figure 1: Biosimilars in Developed Countries, Size and Complexity- Small Molecule Drugs and Proteins, 2011
  • Figure 2: Biosimilars in Developed Countries, Size and Complexity- Small Molecule Drugs and Proteins, 2011
  • Figure 3: Biosimilars in Developed Countries, Global Biologics Market Size 2010-2018, Sales by Major Drug Classes in Developed Countries, 2010
  • Figure 4: Biosimilars in Developed Countries, Top 10 Biologics, 2010
  • Figure 5: Biosimilars in Developed Countries, Biopharmaceutical and Biosimilars Manufacturing, 2011
  • Figure 6: Biosimilars in Developed Countries, Market Overview, Cost and Timeline for Developing a Biosimilar, 2011
  • Figure 7: Biosimilars in Developed Countries, Global Biosimilars Market, Geographic Landscape, Regulatory Landscape, 2011
  • Figure 8: Biosimilars in Developed Countries, Global, Market Forecasts ($m), 2011-2018
  • Figure 9: Biosimilars in Developed Countries, Global Biosimilars Market , Geographic Landscape, Drivers and Barriers, 2011
  • Figure 10: Biosimilars in Developed Countries, US Biosimilars Market, Revenue Forecasts ($m), 2011-2018
  • Figure 11: Biosimilars in Developed Countries, Objectives of Biosimilar Legislation and Regulatory Frameworks, 2012
  • Figure 12: Biosimilars in Developed Countries, US, Regulatory Bodies for Biologics, 2012
  • Figure 13: Biosimilars in Developed Countries, US, Regulatory Bodies for Biologics, 2012
  • Figure 14: Biosimilars in Developed Countries, US, Drug Development and Approval Process, 2010
  • Figure 15: Biosimilars in Developed Countries, US, Evolution of Regulatory Pathway, 2012
  • Figure 16: Biosimilars in Developed Countries, US, Impact of Data Exclusivity Period on Biosimilars Development, 2010
  • Figure 17: Biosimilars in Developed Countries, US, Patent Litigation Provisions in BPCIA - Round 1, 2010
  • Figure 18: Biosimilars in Developed Countries, US, Patent Litigation Provisions in BPCIA - Round 2, 2010
  • Figure 19: Biosimilars in Developed Countries, US, Drivers and Barriers for the Biosimilars Market, 2011
  • Figure 20: Biosimilars in Developed Countries, Top Five European Biosimilars Market, Revenue Forecasts ($m), 2011-2018
  • Figure 21: Biosimilars in Developed Countries, Drug Approval Process, Europe, 2011
  • Figure 22: Biosimilars in Developed Countries, Evolution of Regulatory Pathway for Approval of Biosimilars, Europe, 2011
  • Figure 23: Biosimilars in Developed Countries, General and Product Specific Guidelines for Biosimilars, Europe, 2011
  • Figure 24: Biosimilars in Developed Countries, Approval Process for Biosimilars, Europe, 2011
  • Figure 25: Biosimilars in Developed Countries, Data and Market Exclusivity Periods, Europe, 2011
  • Figure 26: Biosimilars in Developed Countries, Comparability Exercises, Europe, 2011
  • Figure 27: Biosimilars in Developed Countries, Number of Biosimilar Applications, Europe, 2004-2009
  • Figure 28: Biosimilars in Developed Countries, Key Issues Facing Biosimilars Market, Europe, 2011
  • Figure 29: Biosimilars in Developed Countries, Drivers and Barriers for the Biosimilars Market, Europe, 2009-2016
  • Figure 30: Biosimilars in Developed Countries, Drivers and Barriers for the Biosimilars Market, the UK, 2011
  • Figure 31: Biosimilars in Developed Countries, Drivers and Barriers for the Biosimilars Market, Germany, 2011
  • Figure 32: Biosimilars in Developed Countries, Drivers and Barriers for the Biosimilars Market, France, 2011
  • Figure 33: Biosimilars in Developed Countries, Drivers and Barriers for the Biosimilars Market, Spain, 2011
  • Figure 34: Biosimilars in Developed Countries, Drivers and Barriers for the Biosimilars Market, Italy, 2011
  • Figure 35: Biosimilars in Developed Countries, Japan Biosimilar Market, Revenue Forecasts ($m), 2011-2018
  • Figure 36: Biosimilars in Developed Countries, Evolution of Regulatory Pathway, Japan, November 2011
  • Figure 37: Biosimilars in Developed Countries, Drivers and Barriers for the Biosimilars Market, Japan, 2011
  • Figure 38: Biosimilars in Developed Countries, Human Growth Hormone Biosimilars Market, Revenue Forecasts ($m), 2011-2018
  • Figure 39: Biosimilars in Developed Countries, Erythropoietin Biosimilars Market, Drivers and Barriers, 2011
  • Figure 40: Biosimilars in Developed Countries, Erythropoietin Biosimilars Market, Revenue Forecasts ($m), 2011-2018
  • Figure 41: Biosimilars in Developed Countries, Erythropoietin Biosimilars Market, Marketed Products Outside the US and EU, 2011
  • Figure 42: Biosimilars in Developed Countries, Erythropoietin Biosimilars Market, Drivers and Barriers, 2011
  • Figure 43: Biosimilars in Developed Countries, Granulocyte-Colony Stimulating Factor Biosimilars Market, Revenue Forecasts ($m), 2011-2018
  • Figure 44: Biosimilars in Developed Countries, Granulocyte-Colony Stimulating Factor Biosimilars Market, Marketed Products Outside the US and EU, 2011
  • Figure 45: Biosimilars in Developed Countries, Granulocyte-Colony Stimulating Factor Biosimilars Market, Drivers and Barriers, 2011
  • Figure 46: Biosimilars in Developed Countries, Interferon alpha Biosimilars Market, Revenue Forecasts ($m), 2012-2018
  • Figure 47: Biosimilars in Developed Countries, Interferon alpha Biosimilars Market, Marketed Products Outside the US and the EU, 2011
  • Figure 48: Biosimilars in Developed Countries, Interferon beta Biosimilars Market, Revenue Forecasts ($m), 2012-2018
  • Figure 49: Biosimilars in Developed Countries, Interferon alpha and Interferon beta Biosimilars Market, Drivers and Barriers, 2011
  • Figure 50: Biosimilars in Developed Countries, Insulin and Insulin Analogs Biosimilars Market, Revenue Forecasts ($m), 2012-2018
  • Figure 51: Biosimilars in Developed Countries, Insulin and Insulin Analogs Biosimilars Market, Drivers and Barriers, 2011
  • Figure 52: Biosimilars in Developed Countries, TNF-alpha Inhibitor Biosimilars Market, Revenue Forecasts ($m), 2015-2018
  • Figure 53: Biosimilars in Developed Countries, TNF-alpha Inhibitor Biosimilars Market, Drivers and Barriers, 2011
  • Figure 54: Biosimilars in Developed Countries, Biosimilars Market for Monoclonal Antibodies Against Cancer, Revenue Forecasts ($m), 2014-2018
  • Figure 55: Biosimilars in Developed Countries, Biosimilars Market for Monoclonal Antibodies Against Cancer, Drivers and Barriers, 2011
  • Figure 56: Biosimilars in Developed Countries, Case Study, Biosimilars and Originator Sales in the EU Market ($m), 2007-2009
  • Figure 57: Biosimilars in Developed Countries, Case Study, Biosimilars and Originator's Eprex Market Share in Germany (%), 2007-2009
  • Figure 58: Biosimilars in Developed Countries, Case Study, Estimates of Generic Discount Offered in the US (%), 2005
  • Figure 59: Biosimilars in Developed Countries, Case Study, Discount on Biosimilars(%), 2007-2009
  • Figure 60: Biosimilars in Developed Countries, Market Overview, Eprex Branded vs. Generic Price Comparison (1000 I.E./0.5ml) ($), 2011
  • Figure 61: Biosimilars in Developed Countries, Industry Dynamics, Strategies Adopted By Branded Biologic Company to Beat Generic Competition, 2011
  • Figure 62: Biosimilars in Developed Countries, Industry Dynamics, Strategies To Be Adopted by Companies to Enter Biosimilar Market
  • Figure 63: Biosimilars in Developed Countries, Competitive Landscape, Celltrion SWOT Analysis, 2011
  • Figure 64: Biosimilars in Developed Countries, Competitive Landscape, Dr Reddy's Laboratories SWOT Analysis, 2011
  • Figure 65: Biosimilars in Developed Countries, Competitive Landscape, Hospira SWOT Analysis, 2011
  • Figure 66: Biosimilars in Developed Countries, Competitive Landscape, Biocon SWOT Analysis, 2011
  • Figure 67: Biosimilars in Developed Countries, Competitive Landscape, Teva Pharmaceuticals Ltd SWOT Analysis, 2011
  • Figure 68: Biosimilars in Developed Countries, Competitive Landscape, Sandoz SWOT Analysis, 2011
  • Figure 69: Biosimilars in Developed Countries, Competitive Landscape, 3SBio SWOT Analysis, 2011
  • Figure 70: Biosimilars in Developed Countries, Competitive Landscape, Intas Pharma SWOT Analysis, 2011
  • Figure 71: Biosimilars in Developed Countries, Competitive Landscape, Samsung Biologics SWOT Analysis, 2011
  • Figure 72: Biosimilars in Developed Countries, Strategic Consolidations, Deals by Type, 2009-2012
  • Figure 73: Biosimilars in Developed Countries, Strategic Consolidations, M&A Deals by Year, 2009-2011
  • Figure 74: Biosimilars in Developed Countries, Strategic Consolidations, M&A Deals by Value, 2009-2011
  • Figure 75: Biosimilars in Developed Countries, Strategic Consolidations, M&A Deals by Geography, 2009-2011
  • Figure 76: Biosimilars in Developed Countries, Strategic Consolidations, Licensing Deals by Year, 2009-2011
  • Figure 77: Biosimilars in Developed Countries, Strategic Consolidations, Licensing Deals by Value, 2009-2011
  • Figure 78: Biosimilars in Developed Countries, Strategic Consolidations, Licensing Deals by Geography, 2009-2011
  • Figure 79: Biosimilars in Developed Countries, Strategic Consolidations, Co-Development Deals by Year, 2010-2011
  • Figure 80: Biosimilars in Developed Countries, Strategic Consolidations, Co- Development Deals by Value, 2009-2012
  • Figure 81: Biosimilars in Developed Countries, Strategic Consolidations, Co-Development Deals by Geography, 2009-2012
Back to Top